BioSkyrb Genomics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

BioSkryb Genomics is a private company founded in 2015 that has developed a proprietary, integrated single-cell multiomics platform. Its patented PTA technology achieves >95% genome coverage from a single cell, which it combines with RNA and protein data in a single workflow to resolve cellular heterogeneity missed by bulk sequencing. The company targets the research, biopharma, and diagnostic markets with its kits and bioinformatics software, aiming to enable breakthroughs in oncology, neurology, and AI-driven precision medicine by providing complete biological data from limited samples.

OncologyNeurology

Technology Platform

Primary Template-directed Amplification (PTA) for high-coverage, uniform whole genome amplification from single cells, integrated with full-length transcriptome and surface protein analysis in a unified multiomics workflow.

Opportunities

The growing need to analyze ultra-low input and QNS (Quantity Not Sufficient) clinical samples, such as fine-needle aspirates and archived FFPE tissues, represents a major unmet need in diagnostics that BioSkryb's sensitive platform can address.

Furthermore, the demand for high-fidelity, integrated multiomic datasets to train AI/ML models for precision medicine creates a significant partnership opportunity with biopharma and tech companies.

Risk Factors

Intense competition from larger, well-funded single-cell analysis companies poses a significant market penetration challenge.

The complexity and potential cost of the platform may limit adoption to niche applications unless clear, superior return on investment is demonstrated.

As a private company, reliance on external funding and a longer sales cycle for clinical adoption introduces financial and execution risk.

Competitive Landscape

BioSkryb competes in the single-cell analysis market against dominant players like 10x Genomics (Chromium platform) and Becton Dickinson (BD Rhapsody), which offer robust single-cell RNA-seq and limited multiomics but lack equivalent whole-genome coverage fidelity. It also competes with other whole-genome amplification specialists and newer multiomics startups. BioSkryb's key differentiator is the combination of high-coverage single-cell DNA analysis with integrated RNA/protein data in one workflow.

More companies in Diagnostics & Precision Medicine →More companies in United States →